1.Changes and significance of T lymphocyte subsets and cytokines in hyperlipidemia-induced acute pancreatitis
Xiaodong HUANG ; Jiyan LIN ; Penghui DU ; Xianwei HUANG ; Mandong PAN ; Qicong WANG ; Jianbao HUANG ; Qingliu ZHENG ; Qiqi WU ; Jun HU
Chinese Journal of Emergency Medicine 2022;31(1):92-97
Objective:To explore the characteristics of T lymphocyte subsets and cytokines in hyperlipidemia-induced acute pancreatitis (HLAP) and its prognostic value.Methods:This study included 184 patients with acute pancreatitis (AP) admitted to the First Affiliated Hospital of Xiamen University from January 2018 to May 2021. Based on disease etiology, there were 92 HLAP cases and 92 non-hyperlipidemia-induced AP (NHLAP) cases. Stratified by disease severity according to 2012 Atlanta classification criteria, the patients were divided into the severe subgroup (SAP) and non-severe subgroup (NSAP). Peripheral venous blood samples were taken from all patients on day 1, 3, and 5 after admission. T lymphocyte subsets were determined by flow cytometry, and cytokines were detected by flow fluorometry. The number of CD4 +% and CD8 +% and the expression of cytokines were compared by Student’s t test or Mann-Whitney U analysis. Logistic regression analyses were performed to identify risk factors for severe AP, and a receiver operating characteristic (ROC) curve was constructed to predict severe AP. Statistical significance was taken as P<0.05. Results:Compared with the NHLAP group, patients in the HLAP group had lower CD4 +%, while higher levels of IL-2 on day 1 ( P<0.05), and had also lower CD4 +%, while higher levels of IL-4, IL-6, and IL-10 on day 3 ( P<0.05). Furthermore, IL-6 and IL-10 levels of the HLAP group were significantly increased compared to the NHLAP group on day 5 ( P<0.05). IL-10 levels in the SAP subgroup were significantly higher than those in the NSAP subgroup on day 1 ( P<0.05). Compared with the NSAP subgroup, the SAP subgroup had elevated levels of IL-2, IL-4, IL-6, IL-10 and IFN-γ on day 3 (all P<0.05), and had lower CD4 +%, while increased levels of IL-6 and IL-10 on day 5 (all P<0.05). Multivariate Logistic regression analysis showed that IL-10 was an immune indicator of independent risk factor for severe AP in the HLAP group on day 1 ( OR=1.139, 95% CI: 1.038-1.251, P<0.05). Finally, ROC analysis showed that the area under the curve of IL-10 to assess HLAP with severe AP was 0.772, and the best cut-off value for predicting severe AP was 5.6 pg/mL, with a sensitivity of 83.3% and a specificity of 68.8%. Conclusions:Changes of CD4 +% and cytokines are different between the HLAP and NHLAP groups. IL-10 can be used as a predictor of early disease severity in patients with HLAP.
2.Research Progresses on Pharmaceutical Co-crystals of the Cardiovascular and Cerebrovascular Diseases Treatment Drugs
Penghui YUAN ; Dezhi YANG ; Kun HU ; Guanhua DU ; Li ZHANG ; Yang LYU
Herald of Medicine 2019;38(2):187-192
The pharmaceutical co-crystal has attracted a lot of attention in recent years as a new direction in the research of polymorphism drugs. The research on pharmaceutical co-crystal has scientific significance for improving the solubility, bioavailability and physical or chemical stability of drugs. In this paper, from the perspective of drugs for the treatment of cardiovascular diseases(including five major types: heart failure, hypertension, coronary heart disease and arrhythmia, stroke) , the latest research results of pharmaceutical co-crystal reported in recent years are reviewed, hope to provide reference for the follow-up research and promote the development of pharmaceutical co-crystal in China.
3.Correlation between HDAC4 gene polymorphism and essential hypertension
Hongli CHEN ; Hui HUANG ; Penghui DU ; Biwen CHEN ; Zhong WANG
Journal of Xi'an Jiaotong University(Medical Sciences) 2022;43(5):697-702
【Objective】 To explore the relationship of histone deacetylase 4 (HDAC4) gene rs1108519 and rs3791398 polymorphisms with essential hypertension. 【Methods】 Totally 212 patients with essential hypertension were selected, and 212 healthy people were matched as the control group according to the principle of the same sex and age of ±2 years. Sanger sequencing was used to determine the genotype. SPSS22.0 software was used to compare and analyze the relationship of clinical data and gene polymorphisms with essential hypertension. 【Results】 ① Compared with those in the control group, age, BMI, pulse pressure difference, mean arterial pressure, uric acid, triglyceride, RV5, and RV5+SV1 were higher, heart rate was faster, and HDL was lower in hypertension group (all P<0.05). There was no significant difference in the other clinical data (all P>0.05). ② The genotype distribution of the two loci in the two groups were in accordance with Hardy-Weinberg equilibrium (all P>0.05). Compared with the control group, hypertension group had lower frequencies of genotype AA and allele A in rs1108519 locus, but higher frequencies of genotype AG, GG and allele G (all P<0.05). There was no significant difference in genotype or allele frequency distribution between the two groups at rs3791398 locus (all P>0.05). ③ After adjusting for possible confounding, the risk of hypertension in the population with AG and GG genotypes in rs1108519 locus was 5.980 times (OR=5.980, 95% CI: 1.334-26.811, P=0.019) and 2.832 times (OR=2.832, 95% CI: 1.466-5.472, P=0.002) that of AA genotype, respectively. Under the dominant model, the risk of hypertension in subjects with AG or GG genotype was 3.207 times higher than that with AA genotype (OR=3.207, 95% CI: 1.739-5.917, P<0.001). Under the recessive model, the risk of hypertension in subjects with AG or AA genotype was 19.3% of that with GG genotype (OR=0.193, 95% CI: 0.045-0.825, P=0.026). The risk of hypertension in subjects with allele G was 1.816 times higher than that with allele A (OR=1.816, 95% CI: 1.281-2.575, P=0.001). There was no significant difference in the risk of hypertension among people with different genotypes and alleles at rs3791398 locus (all P>0.05). 【Conclusion】 HDAC4 gene rs1108519 locus polymorphism is related to hypertension, and the G allele may be a risk factor for the onset of essential hypertension.
4.Comprehensive analysis of RNA-seq and whole genome sequencing data reveals no evidence for SARS-CoV-2 integrating into host genome.
Yu-Sheng CHEN ; Shuaiyao LU ; Bing ZHANG ; Tingfu DU ; Wen-Jie LI ; Meng LEI ; Yanan ZHOU ; Yong ZHANG ; Penghui LIU ; Yong-Qiao SUN ; Yong-Liang ZHAO ; Ying YANG ; Xiaozhong PENG ; Yun-Gui YANG
Protein & Cell 2022;13(5):379-385
5.Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity.
Fuhua WU ; Shuang LUO ; Yongshun ZHANG ; Yangsen OU ; Hairui WANG ; Zhaofei GUO ; Chunting HE ; Shuting BAI ; Penghui HE ; Min JIANG ; Xiaoyan CHEN ; Guangsheng DU ; Xun SUN
Acta Pharmaceutica Sinica B 2023;13(5):2219-2233
Due to the insufficient long-term protection and significant efficacy reduction to new variants of current COVID-19 vaccines, the epidemic prevention and control are still challenging. Here, we employ a capsid and antigen structure engineering (CASE) strategy to manufacture an adeno-associated viral serotype 6-based vaccine (S663V-RBD), which expresses trimeric receptor binding domain (RBD) of spike protein fused with a biological adjuvant RS09. Impressively, the engineered S663V-RBD could rapidly induce a satisfactory RBD-specific IgG titer within 2 weeks and maintain the titer for more than 4 months. Compared to the licensed BBIBP-CorV (Sinopharm, China), a single-dose S663V-RBD induced more endurable and robust immune responses in mice and elicited superior neutralizing antibodies against three typical SARS-CoV-2 pseudoviruses including wild type, C.37 (Lambda) and B.1.617.2 (Delta). More interestingly, the intramuscular injection of S663V-RBD could overcome pre-existing immunity against the capsid. Given its effectiveness, the CASE-based S663V-RBD may provide a new solution for the current and next pandemic.